Home > Riviste > Minerva Gastroenterology > Fascicoli precedenti > Minerva Gastroenterology 2021 March;67(1) > Minerva Gastroenterology 2021 March;67(1):38-49

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW  NEW PERSPECTIVES IN HEPATOLOGY: MANAGEMENT OF COMPLEX LIVER DISEASES 

Minerva Gastroenterology 2021 March;67(1):38-49

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Hepatocellular carcinoma risk in patients with HBV-related liver disease receiving antiviral therapy

Sara BATTISTELLA, Erica N. LYNCH, Martina GAMBATO, Alberto ZANETTO, Monica PELLONE, Sarah SHALABY, Salvatore S. SCIARRONE, Alberto FERRARESE, Giacomo GERMANI, Marco SENZOLO, Patrizia BURRA, Francesco P. RUSSO

Unit of Gastroenterology and Multivisceral Transplant, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padua, Padua, Italy


PDF


Hepatitis B virus (HBV) is a major health problem worldwide, with approximatively 240 million people living with a chronic HBV infection. HBV chronic infection remains the major cause of hepatocellular carcinoma worldwide, with more than half of HCC patients being chronic HBV carriers, even if underlying mechanisms of tumorigenesis are not totally understood. HBV-related HCC can be prevented by reducing the exposure to HBV by vaccination or by treatment of CHB infection. Current treatment of CHB are Peg-IFN alpha and oral NUCs. Treating HBV infection, either with IFN or NUCs, substantially reduces the risk of HCC development, even if antiviral therapy fails to completely eliminate HCC risk. Among treated patients, cirrhosis, HBeAg negative at baseline and failure to remain in virological remission were associated with an increased risk of HCC. The reduction of the risk of developing HCC during antiviral therapy is largely dependent upon the maintenance of virological remission, since viral load is found to be the most important factor leading to cirrhosis and its complications, including liver cancer development. The question whether Peg-IFN-alpha is superior to NUCs and whether there is a superior agent among NUCs is still controversial. Several studies demonstrated that antiviral therapy with NUCs could reduce the risk of HCC recurrence after curative treatment of HBV-related HCC.


KEY WORDS: Carcinoma, hepatocellular; Liver cirrhosis; Hepatitis B virus

inizio pagina